Related content

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By Ackerman Allison   Klein Oliver   McDermott David F.   Wang Wei   Ibrahim Nageatte   Lawrence Donald P.   Gunturi Anasuya   Flaherty Keith T.   Hodi F. Stephen   Kefford Richard   Menzies Alexander M.   Atkins Michael B.   Long Georgina V.   Sullivan Ryan J.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

Blackwell Publishing

Access to resources Recommend Favorite

Emerging BRAF inhibitors for melanoma

By Sabbatino Francesco   Wang Yangyang   Wang Xinhui   Ferrone Soldano   Ferrone Cristina R  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 4, 2013-12 ,pp. : 431-443

Informa Healthcare

Access to resources Recommend Favorite

A Novel Treatment Approach for Extensive, Eruptive, Cutaneous Squamous Cell Carcinomas in a Patient Receiving BRAF Inhibitor Therapy for Metastatic Melanoma

By Fathi Ramin   Kamalpour Loebat   Gammon Bryan   Tung Rebecca  

Dermatologic Surgery, Vol. 39, Iss. 2, 2013-02 ,pp. : 341-344

Elsevier

Access to resources Recommend Favorite

Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies

By Sharma Anant   Shah Sachin R.   Illum Henrik   Dowell Jonathan  

Drugs, Vol. 72, Iss. 17, 2012-12 ,pp. : 2207-2222

Adis International

Access to resources Recommend Favorite

Secondary tumours with BRAF-inhibitors sparked by mutations

By  

Reactions Weekly, Vol. 1, Iss. 1389, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite